Login to My NLA Account

News Stories

May, 2024

Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed hyperlipidemia population with plozasiran (MUIR study with APOC3 target) and zodasiran (ARCHES2 study with ANGPTL3 target) following the EAS presentations by Drs. Ballantyne and Rosenson.

The press releases with manuscript information can be accessed here. 

0
No votes yet
Name: NLA News
Sep, 2023

 

  • Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo
  • First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent 
  • Olezarsen demonstrated a favorable safety and tolerability profile
  • Ionis plans to file a New Drug Application with U.S. FDA in preparation for first potential independent launch

0
No votes yet
Name: NLA News
Sep, 2023

The United States Preventive Services Task Force (USPSTF) recently released its Final Recommendation Statement on Lipid Disorders in Children and Adolescents: Screening. NLA leadership disagrees with this release and communicated twice to USPSTF about the implications of this statement. The USPSTF has made no acknowledgment of the NLA’s concerns.

0
No votes yet
Name: NLA News